Role of HIV-1 Integrase in the Late Stage of Viral Replication

HIV-1整合酶在病毒复制后期的作用

基本信息

  • 批准号:
    8732362
  • 负责人:
  • 金额:
    $ 19.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-02-01 至 2016-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): HIV-1 integrase (IN) is essential for viral replication and thus is an important therapeutic target. During the early stages of viral replication, a tetramer of HIV-1 IN catalyzes integration of reverse transcribed viral DNA into the host genome. The ordered multimerization of IN in the presence of viral DNA is critical for IN catalytic activity. Cellular cofactor LEDGF/p75 binds to the pre-assembled IN- viral DNA complex and tethers the nucleoprotein complex to active genes, thus ensuring effective integration. Allosteric integrase inhibitors (ALLINIs) are a novel class of integrase inhibitors that bind at the LEDGF/p75 binding site at the IN dimer interface and are capable of triggering aberrant IN multimerization. In addition, HIV-1 virions produced in the presence of ALLINIs display abnormal morphology of the virion cores and are defective for subsequent reverse transcription and integration in target cells. Interestingly, these phenotypes are similar to certain IN mutants, which have been termed class II mutants. Collectively, the studies with ALLINIs and select IN class II mutants suggest that HIV-1 IN plays a key role during late stage HIV-1 replication. However, the underlying mechanism is not clear. The present application will test the following hypothesis: ordered IN multimerization is important for its interaction with viral RNA during the late stage viral replication. Therefore, we propose the following two specific aims. Aim 1 will explore the significance of HIV-1 IN interactions with RNA for formation of the functional ribonuleoprotein complexes during the late stage viral replication. Aim 2 will characterize IN mutants that affect IN multimerization and/or IN- LEDGF/p75 binding. Mechanistic and structural details that will emerge from these studies will inform drug discovery efforts to develop improved ALLINIs for their clinical application.
描述(由申请人提供):HIV-1整合酶(IN)对病毒复制至关重要,因此是重要的治疗靶点。在病毒复制的早期阶段,HIV-1 IN的四聚体催化逆转录的病毒DNA整合到宿主基因组中。IN在病毒DNA存在下的有序多聚化对于IN催化的多聚化是至关重要的。 活动细胞辅因子LEDGF/p75与预组装的IN-病毒DNA复合物结合,并将核蛋白复合物与活性基因结合,从而确保有效整合。变构整合酶抑制剂(ALLINI)是一类新型的整合酶抑制剂,其在IN二聚体界面的LEDGF/p75结合位点处结合,并且能够触发异常IN多聚化。此外,在ALLINI存在下产生的HIV-1病毒体显示病毒体核心的异常形态,并且对于随后的逆转录和在靶细胞中的整合是有缺陷的。有趣的是,这些表型与某些IN突变体相似,这些IN突变体被称为II类突变体。总的来说,ALLINI和选择IN II类突变体的研究表明,HIV-1 IN在晚期HIV-1复制中起关键作用。然而,其内在机制尚不清楚。本申请将测试以下假设:有序IN多聚化对于其在后期病毒复制期间与病毒RNA的相互作用是重要的。因此,我们提出以下两个具体目标。目的1探讨HIV-1 IN与RNA相互作用在病毒复制后期形成功能性核糖核蛋白复合物中的意义。目的2将表征影响IN多聚化和/或IN-LEDGF/p75结合的IN突变体。从这些研究中出现的机制和结构细节将为药物发现工作提供信息,以开发改进的ALLINI用于其临床应用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jacques J. Kessl其他文献

Jacques J. Kessl的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jacques J. Kessl', 18)}}的其他基金

New Inhibitors Targeting HIV-1 Integrase During Viral Maturation
在病毒成熟过程中针对 HIV-1 整合酶的新型抑制剂
  • 批准号:
    10218004
  • 财政年份:
    2019
  • 资助金额:
    $ 19.22万
  • 项目类别:
New Inhibitors Targeting HIV-1 Integrase During Viral Maturation
在病毒成熟过程中针对 HIV-1 整合酶的新型抑制剂
  • 批准号:
    10452601
  • 财政年份:
    2019
  • 资助金额:
    $ 19.22万
  • 项目类别:
Mode of Action of Allosteric HIV-1 Integrase Inhibitors during Late Steps of Viral Replication
变构 HIV-1 整合酶抑制剂在病毒复制后期的作用模式
  • 批准号:
    9204097
  • 财政年份:
    2016
  • 资助金额:
    $ 19.22万
  • 项目类别:
Role of HIV-1 Integrase in the Late Stage of Viral Replication
HIV-1整合酶在病毒复制后期的作用
  • 批准号:
    8793750
  • 财政年份:
    2014
  • 资助金额:
    $ 19.22万
  • 项目类别:
Inhibitors Targeting HIV Integrase Multimers
针对 HIV 整合酶多聚体的抑制剂
  • 批准号:
    8294551
  • 财政年份:
    2011
  • 资助金额:
    $ 19.22万
  • 项目类别:
Inhibitors Targeting HIV Integrase Multimers
针对 HIV 整合酶多聚体的抑制剂
  • 批准号:
    8210639
  • 财政年份:
    2011
  • 资助金额:
    $ 19.22万
  • 项目类别:
Developmental Research Project Core
发展研究项目核心
  • 批准号:
    10623978
  • 财政年份:
    2001
  • 资助金额:
    $ 19.22万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 19.22万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.22万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 19.22万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.22万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 19.22万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.22万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 19.22万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 19.22万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 19.22万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.22万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了